Ongoing (recruiting) chemotherapy-free combination regimens
| Regimen . | Study phase . | Disease setting . | Identifier . |
|---|---|---|---|
| Ibrutinib, obinutuzumab | 1/2 | TN | NCT02315768 |
| Ibrutinib, obinutuzumab | 1 | R/R | NCT02537613 |
| High dose ibrutinib, obinutuzumab | 1 | In patients with progressive disease on ibrutinib | NCT02611908 |
| Ibrutinib, nivolumab | 2 | R/R | NCT02420912 |
| Ibrutinib, pembrolizumab | 1/2 | R/R | NCT03153202 |
| Pembrolizumab alone or with idelalisib or ibrutinib | 2 | R/R | NCT02332980 |
| Ibrutinib, obinutuzumab, atezolizumab | 2 | High-risk TN, R/R | NCT02846623 |
| Ibrutinib, daratumumab | 1 | TN | NCT03447808 |
| Ibrutinib, selinexor | 1 | R/R | NCT02303392 |
| Ibrutinib, pevonedistat | 1 | R/R | NCT03479268 |
| Ibrutinib, crimtuzumab (anti-ROR1 mAb) | 1/2 | TN, RR | NCT03420183 |
| Ibrutinib, BNC105P (vascular disrupting agent) | 1 | R/R | NCT03454165 |
| Ibrutinib, VAY736 (anti-BAFF-R mAb) | 1 | Lack of CR on ibrutinib or known ibrutinib resistance mutation | NCT03400176 |
| Venetoclax, high dose ibrutinib | 1 | In patients with progressive disease on ibrutinib | NCT03422393 |
| Venetoclax, duvelisib | 1/2 | R/R | NCT03534323 |
| Venetoclax, ublituximab, umbralisib (TGR-1202) | 1/2 | R/R | NCT03379051 |
| Acalabrutinib, venetoclax, obinutuzumab (AVO) | 2 | TN | NCT03580928 |
| Acalabrutinib, obinutuzumab | 1 | R/R | NCT02296918 |
| Acalabrutinib, AZD6738 (ATR inhibitor) | 1/2 | R/R | NCT03328273 |
| Regimen . | Study phase . | Disease setting . | Identifier . |
|---|---|---|---|
| Ibrutinib, obinutuzumab | 1/2 | TN | NCT02315768 |
| Ibrutinib, obinutuzumab | 1 | R/R | NCT02537613 |
| High dose ibrutinib, obinutuzumab | 1 | In patients with progressive disease on ibrutinib | NCT02611908 |
| Ibrutinib, nivolumab | 2 | R/R | NCT02420912 |
| Ibrutinib, pembrolizumab | 1/2 | R/R | NCT03153202 |
| Pembrolizumab alone or with idelalisib or ibrutinib | 2 | R/R | NCT02332980 |
| Ibrutinib, obinutuzumab, atezolizumab | 2 | High-risk TN, R/R | NCT02846623 |
| Ibrutinib, daratumumab | 1 | TN | NCT03447808 |
| Ibrutinib, selinexor | 1 | R/R | NCT02303392 |
| Ibrutinib, pevonedistat | 1 | R/R | NCT03479268 |
| Ibrutinib, crimtuzumab (anti-ROR1 mAb) | 1/2 | TN, RR | NCT03420183 |
| Ibrutinib, BNC105P (vascular disrupting agent) | 1 | R/R | NCT03454165 |
| Ibrutinib, VAY736 (anti-BAFF-R mAb) | 1 | Lack of CR on ibrutinib or known ibrutinib resistance mutation | NCT03400176 |
| Venetoclax, high dose ibrutinib | 1 | In patients with progressive disease on ibrutinib | NCT03422393 |
| Venetoclax, duvelisib | 1/2 | R/R | NCT03534323 |
| Venetoclax, ublituximab, umbralisib (TGR-1202) | 1/2 | R/R | NCT03379051 |
| Acalabrutinib, venetoclax, obinutuzumab (AVO) | 2 | TN | NCT03580928 |
| Acalabrutinib, obinutuzumab | 1 | R/R | NCT02296918 |
| Acalabrutinib, AZD6738 (ATR inhibitor) | 1/2 | R/R | NCT03328273 |
mAb, monoclonal antibody.